A5006924305- Immunotherapy and Immune Responses
- Cervical Cancer and HPV Research
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- RNA Interference and Gene Delivery
- vaccines and immunoinformatics approaches
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- CAR-T cell therapy research
- Nanoplatforms for cancer theranostics
- Immune cells in cancer
- Herpesvirus Infections and Treatments
- Respiratory viral infections research
- Animal Virus Infections Studies
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Genital Health and Disease
- Ovarian cancer diagnosis and treatment
- Viral-associated cancers and disorders
- Toxin Mechanisms and Immunotoxins
- Polyomavirus and related diseases
- Colorectal and Anal Carcinomas
Changi General Hospital
2025
Chung Shan Medical University
2025
Southern Medical University
2025
Johns Hopkins University
2015-2024
Johns Hopkins Medicine
2014-2024
United States Nuclear Regulatory Commission
2023
University of Baltimore
2010-2021
Beijing Obstetrics and Gynecology Hospital
2001-2014
Bipar
2001-2014
Sidney Kimmel Comprehensive Cancer Center
2013-2014
About 25% of high-grade cervical intraepithelial neoplasias (CIN2/3) caused by human papillomavirus serotype 16 (HPV16) undergo complete spontaneous regression. However, to date, therapeutic vaccination strategies for HPV disease have yielded limited success when measured their ability induce robust peripheral blood T cell responses vaccine antigen. We report marked immunologic changes in the target lesion microenvironment after intramuscular targeting HPV16 E6/E7 antigens, subjects with...
The presentation of antigenic peptides by major histocompatibility complex (MHC) class II molecules to CD4+ T cells is critical the function immune system. In this study, we have utilized sorting signal lysosomal-associated membrane protein LAMP-1 target a model antigen, human papillomavirus 16 E7 (HPV-16 E7), into endosomal and lysosomal compartments. reroutes antigen MHC processing pathway, resulting in enhanced vitro. vivo immunization experiments mice demonstrated that vaccinia...
Antigen-specific cancer immunotherapy and antiangiogenesis have emerged as two attractive strategies for treatment. An innovative approach that combines both mechanisms will likely generate the most potent antitumor effect. We tested this using calreticulin (CRT), which has demonstrated ability to enhance MHC class I presentation exhibit an antiangiogenic explored linkage of CRT a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, development DNA vaccine. found C57BL/6 mice...
Antigen-specific cancer immunotherapy and antiangiogenesis have emerged as two attractive strategies for treatment. An innovative approach that combines both mechanisms will likely generate the most potent antitumor effect. We tested this using calreticulin (CRT), which has demonstrated ability to enhance MHC class I presentation exhibit an antiangiogenic explored linkage of CRT a model tumor antigen, human papilloma virus type-16 (HPV-16) E7, development DNA vaccine. found C57BL/6 mice...
Transcatheter arterial chemoembolization (TACE) improves the treatment of hepatocellular carcinoma (HCC) by causing tumour necrosis and shrinkage. Fifty-two patients with resectable large HCC (defined as a maximal diameter 10 cm or more) were prospectively randomized into two groups: group 1 comprised 24 who had 1-5 sessions TACE before operation; 2 consisted other 28 patients, on whom surgery was performed without delay. Tumour volume reduced to mean (s.d.) 42.8 (15.3) per cent in 16 1, but...
DNA vaccination is an attractive approach for tumor immunotherapy because of its stability and simplicity delivery. Advances demonstrate that helper T cell responses play a critical role in initiating immune responses. The aim the current study to test whether targeting HPV-16 E7 endosomal/lysosomal compartment can enhance potency vaccines. We linked lysosome-associated membrane protein 1 (LAMP-1) HPV-E7 construct chimeric DNA, Sig/E7/LAMP-1 DNA. For vivo prevention experiments, mice were...
Abstract Purpose: To evaluate the safety and immunogenicity of a therapeutic human papillomavirus (HPV)16 DNA vaccine administered to women with HPV16+cervical intraepithelial neoplasia (CIN)2/3. Experimental Design: This phase I trial incorporated standard ′3+3″ dose-escalation design an additional 6 patients allocated maximally tolerated dose. Healthy adult colposcopically directed, biopsy-proven HPV16+ CIN2/3 received 3 i.m. vaccinations (0.5, 1, or mg) plasmid expressing...
Adaptation of tumor cells to the host is a major cause cancer progression, failure therapy, and ultimately death. Immune selection drives this adaptation in human by enriching with stem cell-like (CSC-like) phenotype that makes them resistant CTL-mediated apoptosis; however, mechanisms mediate CSC maintenance proliferation are largely unknown. Here, we report immune evolution toward CSC-like arises through Akt signaling pathway via transcriptional induction Tcl1a Nanog. Furthermore, found...
ABSTRACT Severe acute respiratory syndrome (SARS) is a serious threat to public health and the economy on global scale. The SARS coronavirus (SARS-CoV) has been identified as etiological agent for SARS. Thus, vaccination against SARS-CoV may represent an effective approach controlling DNA vaccines are attractive vaccine development, they offer many advantages over conventional vaccines, including stability, simplicity, safety. Our investigators have previously shown that with antigen linked...
The US Food and Drug Administration (FDA) is currently developing a guidance for industry to replace previous guidance, "Pharmacokinetics in Patients With Impaired Renal Function—Study Design, Data Analysis, Impact on Dosing Labeling" (renal guidance) issued May 1998. impact of the 1998 renal was assessed following survey 94 new drug applications (NDAs) small-molecule molecular entities (NMEs) approved over past 5 years (2003–2007). results indicate that 57% these NDAs included impairment...
Dose-dense (DD) regimens of combination chemotherapy may produce superior clinical outcomes, but the basis for these effects are not completely clear. In this study, we assessed whether a DD combinatorial regimen low-dose cisplatin and paclitaxel produces immune-mediated efficacy when compared with maximum tolerated dose (MTD) in treating platinum-resistant ovarian cancer as modeled mice. Immune responses generated by were identified regard to immune cell subset responsible antitumor...
Because the combination of multiple modalities for cancer treatment is more likely to generate potent therapeutic effects control cancer, we have explored chemotherapy using cisplatin, which routinely used in advanced cervical with immunotherapy DNA vaccines encoding calreticulin (CRT) linked human papillomavirus type 16 E7 antigen (CRT/E7) a preclinical model.We characterized cisplatin CRT/E7 vaccine different regimen its potential ability E7-specific CD8+ T-cell immune responses as well...